CASI Pharmaceuticals, Inc. has 16 Schedule 13D or 13G filings on record since 2025-07-23. 6 holders' latest filing reports 5% or more of ordinary shares. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| WEI-WU HE, Ph.D. | 58.8% | 23,985,535 | SCHEDULE 13D/A, 2026-05-18 | 2026-05-18 |
| Panacea Innovation Limited | 22.5% | 4,529,956 | SCHEDULE 13D/A, 2025-12-17 | 2025-12-16 |
| James Huang | 13.8% | 2,161,571 | SCHEDULE 13G/A, 2025-07-23 | 2025-06-30 |
| Chen Zhenfeng | 11% | 2,255,636 | SCHEDULE 13G, 2025-11-26 | 2025-09-30 |
| Venrock Healthcare Capital Partners III, L.P. | 9.2% | 1,987,259 | SCHEDULE 13G/A, 2026-02-17 | 2025-12-31 |
| Sparkle Byte Ltd | 5% | 1,019,852 | SCHEDULE 13D/A, 2026-01-20 | 2025-09-30 |
| Ho Chi Sing | 4.8% | 915,850 | SCHEDULE 13D/A, 2026-01-20 | 2025-09-30 |
| Foresite Capital Fund VI LP | 0% | 0 | SCHEDULE 13G/A, 2026-02-13 | 2025-12-31 |
Purpose of Transaction (Item 4)
WEI-WU HE, Ph.D.
On April 17, 2026, ETP Global III Fund L.P. purchased a convertible note with the principal amount of US$5 million as the fourth tranche of the Issuer's US$20 million convertible note financing pursuant to certain convertible note purchase agreement (the "Purchase Agreement") between ETP Global III Fund L.P. and the Issuer dated December 11, 2025. A convertible note with a principal amount of US$5 million has been issued to the Purchaser on the same date (the "Convertible Note"). The Purchaser has the right to convert such note into the Company's ordinary shares, par value US$0.0001 per share (the "Ordinary Shares") at any time from and including the 91st day after the issuance thereof to and including the maturity date at a conversion price of the volume weighted average closing price of the Company's Ordinary Shares during the five consecutive trading days immediately preceding the date of conversion notice by ETP Global III Fund L.P. In no event shall the conversion price be higher than US $2 per Ordinary Share or lower than US $1 per Ordinary Share. The descriptions of the Convertible Note are qualified in their entirety by reference to the Convertible Note itself, a copy of which is attached hereto as Exhibit B and incorporated hereby by reference in its entirety. The beneficial ownership reported hereof included Ordinary Shares that the reporting person has the right to acquire within 60 days, through the conversion of such Convertible Note, with an assumed conversion …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-05-18; the filing has the rest
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-23 | James Huang | 13.8% | SCHEDULE 13G/A |
| 2025-08-12 | Foresite Capital Fund VI, L.P. | 5.1% | SCHEDULE 13G/A |
| 2025-09-26 | Panacea Innovation Limited | 19.9% | SCHEDULE 13D |
| 2025-11-14 | Foresite Capital Fund VI LP | 6.3% | SCHEDULE 13G/A |
| 2025-11-26 | Chen Zhenfeng | 11% | SCHEDULE 13G |
| 2025-12-17 | Panacea Innovation Limited | 22.5% | SCHEDULE 13D/A |
| 2025-12-18 | WEI-WU HE, Ph.D. | 19.1% | SCHEDULE 13D/A |
| 2026-01-09 | WEI-WU HE, Ph.D. | 19.1% | SCHEDULE 13D/A |
| 2026-01-20 | Sparkle Byte Ltd | 5% | SCHEDULE 13D/A |
| 2026-01-20 | Ho Chi Sing | 4.8% | SCHEDULE 13D/A |
| 2026-01-29 | WEI-WU HE, Ph.D. | 34.8% | SCHEDULE 13D/A |
| 2026-02-10 | WEI-WU HE, Ph.D. | 45.4% | SCHEDULE 13D/A |
| 2026-02-13 | Foresite Capital Fund VI LP | 0% | SCHEDULE 13G/A |
| 2026-02-17 | Venrock Healthcare Capital Partners III, L.P. | 9.2% | SCHEDULE 13G/A |
| 2026-03-23 | WEI-WU HE, Ph.D. | 53% | SCHEDULE 13D/A |
| 2026-05-18 | WEI-WU HE, Ph.D. | 58.8% | SCHEDULE 13D/A |
CASI Pharmaceuticals, Inc.: every filing and event
Tools for this story
Each opens in a new tab, filled in for CASI Pharmaceuticals, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.